Please refer to Phase I studies for more clinical trial opportunities.

**Melanoma**

**Observational**
- IRB#17104
  - DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Uveal Melanoma**
- IRB#16162:
  - A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

**Adjuvant Therapies**

**Stage 2b, 2c or 3**
- IRB#11848
  - A Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

**Stage 3 or 4 Resectable**
- IRB#15561
  - A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB#16883
  - A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection

**Melanoma**

**Stage 3 or 4, Unresectable**

**Mutation Specific**
- IRB#16198
  - A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

**Non-Mutation Specific**
- IRB# 18687
  - A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.

- IRB# 19207
  - Coming Soon

- IRB# 19285
  - Coming Soon

[Key]
- Open for Enrollment
- In Development
- Enrollment on Hold

[1/7/2019]

http://www.ohsu.edu/research/rda/so/knight.php